|
Treatment
|
Time points
|
|---|
|
12 months
|
24 months
|
36 months
|
48 months
|
|---|
|
NIVO vs. OBS/PBO
|
0.58 (0.43–0.77)
|
0.51 (0.33–0.80)
|
0.46 (0.26–0.86)
|
0.43 (0.21–0.91)
|
|
NIVO vs. DAB+TRAM
|
1.02 (0.71–1.47)
|
0.46 (0.27–0.78)
|
0.28 (0.14–0.59)
|
0.20 (0.08–0.49)
|
|
NIVO vs. PEM
|
1.19 (0.81–1.76)
|
1.06 (0.56–2.05)
|
0.96 (0.40–2.29)
|
0.88 (0.30–2.51)
|
|
NIVO vs. IPI (10 mg/kg)
|
0.69 (0.55–0.86)
|
0.66 (0.46–0.96)
|
0.65 (0.40–1.07)
|
0.64 (0.35–1.17)
|
|
NIVO vs. IPI (3 mg/kg)
|
0.75 (0.54–1.04)
|
0.93 (0.58–1.48)
|
1.06 (0.57–2.01)
|
1.16 (0.54–2.55)
|
|
NIVO vs. CHEM
|
0.63 (0.44–0.89)
|
0.53 (0.32–0.86)
|
0.47 (0.24–0.91)
|
0.42 (0.19–0.95)
|
|
NIVO vs. IFN
|
0.64 (0.48–0.86)
|
0.55 (0.36–0.88)
|
0.49 (0.27–0.93)
|
0.46 (0.22–0.97)
|
- aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatments; bolded values are statistically significant at the 0.05 significance level
- CHEM other chemotherapy, DAB dabrafenib, DFS disease-free survival, HR hazard ratio, IFN interferon, IPI ipilimumab, NIVO nivolumab, NMA network meta-analysis, OBS observation, PBO placebo, PEM pembrolizumab, RFS recurrence-free survival, TRAM trametinib
